Respiratory diseases are prevalent in autumn and winter. An "invisible threat" known as Human Adenovirus Type 55 (HAdV55) is quietly lurking in crowded places—military camps, schools, and hospitals. It can cause high fever, pneumonia, and in severe cases, even be life-threatening! More critically, the virus is highly transmissible with no specific antiviral drugs available, making early rapid detection crucial for prevention and control.
Recently, exciting news has emerged from the East China Medical Research Institute—a Chinese research team dedicated to the development and application of on-site rapid detection technologies for emerging and re-emerging infectious diseases. The team has successfully developed the ERA-CRISPR/Cas12a Nucleic Acid Detection Technology, which can rapidly identify HAdV55 with an impressive sensitivity of 2.5 copies per reaction. Compared with traditional methods, this technology is faster, more sensitive, and more portable!
Human Adenovirus Type 55 (HAdV55) is a potentially hazardous strain within the adenovirus family, classified as a Group B serotype. It is a recombinant of Adenovirus Types 11 and 14. Since its first discovery in China in 2006, it has caused multiple cluster outbreaks.
Primarily transmitted via respiratory droplets, HAdV55 features a short incubation period and high pathogenicity:• Infected individuals may experience symptoms such as fever, cough, and sore throat, which are easily misdiagnosed as the common cold;• In severe cases, it can progress to severe pneumonia, posing a greater threat to immunocompromised populations (e.g., military personnel, students, and the elderly);• Due to the lack of specific antibodies in the general population, large-scale transmission can occur rapidly once an outbreak starts, placing immense pressure on public health prevention and control.
Crucially, there are no specific antiviral drugs available for adenoviruses to date. Early detection and rapid isolation are therefore critical to effective outbreak management.
Historically, HAdV55 detection relied primarily on PCR technology, which has significant drawbacks:
Time-consuming: The entire process takes at least 1 hour (or longer), missing the optimal window for prevention and control;
High equipment costs: Requires specialized PCR instruments, limiting use to laboratory settings and precluding on-site rapid screening;
High operational barriers: Dependent on professionally trained personnel, making it difficult to popularize in primary healthcare facilities or emergency outbreak scenarios.
The newly developed ERA-CRISPR/Cas12a technology completely addresses these pain points!
This cutting-edge technology represents a powerful synergy of two advanced techniques—Enzymatic Recombinase Amplification (ERA) and CRISPR/Cas12a gene editing—operating on the principle of "dual amplification + precise recognition":
ERA is a novel isothermal amplification technology that acts as a "rapid replicator" for viral nucleic acids. Unlike PCR, it does not require thermal cycling (repeated heating and cooling). Instead, it amplifies trace amounts of viral nucleic acids to detectable levels within 20 minutes at a constant temperature of 37-42℃. Most notably, it has extremely low equipment requirements—only a basic constant-temperature device or even a portable instrument is sufficient—making it perfectly suited for on-site detection scenarios.
CRISPR/Cas12a functions like a "genetic detective," equipped with a guide RNA (crRNA) that specifically recognizes the conserved Hexon gene sequence unique to HAdV55. Upon binding to the target sequence, the Cas12a protein is activated: it not only cleaves the viral nucleic acid but also non-specifically cleaves adjacent fluorescent reporter molecules, releasing a fluorescent signal. In simple terms, the presence of the virus is indicated by a distinct fluorescent readout, which can be visualized with the naked eye or a simple detection device.
Combining these two technologies, the entire detection process follows three simple steps:① Extract nucleic acid from the sample (e.g., nasopharyngeal swab);② Perform isothermal amplification at 42℃ for 20 minutes;③ Conduct CRISPR signal amplification at 37℃ for 10 minutes;→ Total time: 30 minutes, with results available immediately!
Experimental data shows that the technology achieves a limit of detection (LOD) as low as 2.5 copies per reaction for live viruses and only 9 copies per reaction for standard plasmids. This means even trace amounts of the virus in samples can be accurately identified, eliminating false negatives.
In comparison, traditional LAMP technology has an LOD of 10 copies per reaction, while RAA technology has an LOD of 18 copies per reaction—representing a doubling or more in sensitivity!
The research team tested 5 common respiratory pathogens (Influenza A, Influenza B, Respiratory Syncytial Virus [RSV], and Mycoplasma pneumoniae) as well as 5 other adenovirus subtypes (HAdV3, 7, 11, 14, 21). The results showed that fluorescent signals were only detected in HAdV55 samples, with no cross-reactivity observed in other pathogens.
Even HAdV11 and 14—subtypes closely related to HAdV55—can be accurately distinguished. This addresses the longstanding challenge of subtype differentiation in traditional detection methods, eliminating misdiagnosis and false judgments.
No complex equipment, no specialized technical personnel—this technology can even be integrated into an all-in-one test kit: simply add the sample, wait 30 minutes, and read the results. Whether in primary hospitals, school infirmaries, or emergency outbreak sites, rapid screening can be deployed immediately.
